Risk Disclaimer: This website/app provides information about the stock market and other investments, we do not recommend buying or selling any stocks including the ones mentioned below. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice (read full disclaimer below)

SPONSORED by Interactive Offers on behalf of YD Bio Limited

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

January 06, 2026 09:00 ET  | Source: YD Bio Limited

Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery. The MOU is non-binding and there can be no assurance that the parties will enter into definitive agreements, obtain required approvals, or consummate the merger on the terms contemplated or on any particular timeline. Any integration benefits, including potential revenue growth, platform expansion, or cost synergies, remain subject to numerous assumptions and risks and may not be realized¹. The transaction is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

Strategic Rationale and Vision for the Future: From Single Technologies to a Platform-Based Biotech Ecosystem

As precision medicine and AI-driven drug development continue to reshape the biotechnology industry, competitive advantage is increasingly defined by the ability to integrate high-quality biological data, advanced analytics, and clinical execution. The Company believes that, if completed, the merger with EG BioMed could result in the acceleration of its anticipated transition from a technology-focused company into a platform-based biotech organization anchored in clinically validated molecular data; however, expected benefits remain subject to successful execution, data generation, regulatory pathways, and market adoption, none of which can be assured. EG BioMed brings to the combined entity a robust DNA methylation diagnostics platform, AI-based biomarker algorithms, and certified clinical laboratory infrastructure, providing the Company with a critical upstream engine for both diagnostics’ commercialization and therapeutic innovation.

By unifying diagnostics, therapeutics, real-world clinical data, and AI intelligence, the Company aims to reduce development risk, accelerate time-to-market, and build a scalable oncology innovation ecosystem addressing cancer from early detection through treatment monitoring and recurrence prevention, subject to successful execution and regulatory and market outcomes.

Synergies: Leveraging DNA Methylation Data for AI-Driven Drug Discovery

EG BioMed’s core technology is based on DNA methylation profiling, a powerful epigenetic approach that captures cancer-associated molecular changes with high sensitivity. Its platform has demonstrated strong clinical performance in early cancer detection, including pancreatic cancer—one of the most lethal malignancies with significant unmet medical needs. Beyond diagnostics, the merger enables YD Bio to transform DNA methylation datasets into strategic assets for AI-powered drug development. These clinically validated epigenetic datasets will be used to support AI-based target discovery, patient stratification, and recurrence-risk prediction. By applying advanced AI models to methylation-driven disease mechanisms, YD Bio aims to develop novel therapeutic approaches with the potential to reduce cancer recurrence and improve long-term patient outcomes.

“Prior to this announcement, EG BioMed’s cancer detection platform was approved for clinical adoption at three affiliated medical centers of Taipei Medical University. It is now being integrated into hospital workflows to assist clinicians in monitoring treatment response, disease progression, and recurrence,” said Dr. Ethan Shen, Chairman and CEO of the Company.” The Company notes that early use at these centers may demonstrate clinical and economic value, which could support wider adoption across additional institutions. Broader uptake, if achieved, may contribute to diagnostics revenue growth and inform future therapeutic development.

About YD Bio Limited

YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and limbal stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com

Forward-Looking Statements

This press release contains forward-looking statements, including, among others, statements regarding the Company’s entrance into a non-binding MOU with EG BioMed, potential merger, including its expected timing, approvals, and potential synergies and platform benefits. Forward-looking statements are based on current expectations, estimates, forecasts, and projections and are not guarantees of future performance. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Actual results may differ materially due to a variety of factors, including regulatory decisions and feedback; the ability to enter into definitive agreements, obtain required approvals, satisfy closing conditions, consummate the transaction on the anticipated timeline or at all, and successfully integrate the businesses. The Company undertakes no obligation to update any forward-looking statements, except as required by law. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

¹ Note to Company: Consider making explicit that the MOU is non-binding / binding, that no assurances can be given that definitive agreements will be entered into / transaction will close on a specific timeline.

ORIGINAL PRESS RELEASE HERE: https://www.globenewswire.com/news-release/2026/01/06/3213679/0/en/YD-Bio-Enters-into-MOU-to-Merge-with-EG-BioMed-Advancing-DNA-Methylation-Driven-AI-Platforms-for-Cancer-Diagnostics-and-Drug-Development.html

IMPORTANT NOTICE AND DISCLAIMER

Copyright 2025 © Stocks.News is owned and operated by IR Agency LLC.

To more fully understand any subscription, website, application, product, or other service (“Services”) including Stocks.News owned or operated by IR Agency LLC (together, with its affiliates, owners, and control persons, the “Publisher”), please review our full disclaimer and other policies located at https://stocks.news/privacy-policy-disclaimer/

Issuer-paid advertisement. YD Bio Ltd (“YDES” or the “Company”) has paid Publisher Two Hundred and Fifty Thousand dollars Cash for marketing services including communicating information about the Company to the Public. This advertorial (“advertisement” or “Advertorial”) is part of those issuer-paid marketing services. The contract with YDES was effective on January 6th 2026 and continue for 1 day (the “Term”) unless it is terminated by written notice of either party prior to the end of the Term or extended. As a result of this advertisement and other marketing efforts, Publisher also may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, Publisher holds no securities of the Company and does not intend to purchase any securities during the Term. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of YDES, increased trading volume, and possibly an increased share price of the YDES’s securities, which may or may not be temporary and decrease once the marketing services have ended.

For Educational and Information Purposes Only; Not Investment Advice. This advertisement is for educational, informational and entertainment purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Publisher cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of this Company or any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the Company that is the subject of the Advertorial or any other companies mentioned in this Advertorial, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this Advertorial or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in the securities of the Company profiled in the Advertorial or any securities of the companies mentioned in this advertisement should do so with caution. Although this advertisement focuses on the positive features of the Company profiled and its securities, you must keep in mind that investing or transacting in these or any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement at most as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Not an Investment Advisor or Registered Broker. Neither Publisher, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Publisher does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the Company profiled in the Advertorial athttps://www.sec.gov/edgar/search/#/ciks=0002011674&entityName=YD%2520Bio%2520Ltd%2520(YDES%252C%2520YDESW)%2520(CIK%25200002011674)

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

COMPENSATION

The owners of IR Agency LLC who also are the publishers of this Advertorial have been paid Two Hundred and Fifty Thousand dollars Cash via bank wire transfer from a third party Interactive Offers on behalf of the Issuer YD Bio Limited (NASDAQ: YDES) for a 1 day marketing program regarding YDES with a start date of January 6th 2026. This Advertorial is a part of that marketing program. The owners do not own stock in YDES. See our important Notice and Disclaimer below for a detailed discussion on compensation.